











































Mutational analysis identifies therapeutic biomarkers in
inflammatory bowel disease-associated colorectal cancers
Citation for published version:
Din, S, Wong, K, Müller, MF, Oniscu, A, Hewinson, J, Black, CJ, Miller, ML, Jiménez-Sánchez, A, Rabbie,
R, Rashid, M, Satsangi, J, Adams, DJ & Arends, MJ 2018, 'Mutational analysis identifies therapeutic
biomarkers in inflammatory bowel disease-associated colorectal cancers', Clinical Cancer Research, vol.
24, no. 20. https://doi.org/10.1158/1078-0432.CCR-17-3713
Digital Object Identifier (DOI):
10.1158/1078-0432.CCR-17-3713
Link:






Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 23. Jul. 2021
 1
Title: Mutational analysis identifies therapeutic biomarkers in inflammatory 
bowel disease-associated colorectal cancers 
 
Authors: 
Shahida Din α, Consultant Gastroenterologist, NHS Lothian, Gastrointestinal Unit, 
Western General Hospital, Edinburgh, Scotland, UK. 
Kim Wong α, Senior Computational Biologist, Wellcome Trust Sanger Institute, 
Hinxton, Cambridge, UK 
Mike F Mueller, Post-doctoral Fellow, Division of Pathology, Centre for Comparative 
Pathology, Edinburgh Cancer Research Centre, Institute of Genetics & Molecular 
Medicine, Western General Hospital, University of Edinburgh, Edinburgh, Scotland, 
UK 
Anca Oniscu, Consultant Pathologist, NHS Lothian, Department of Molecular 
Pathology, Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, Scotland, 
UK 
James Hewinson, Principal Research Associate, Wellcome Trust Sanger Institute, 
Hinxton, Cambridge, UK 
Catherine J Black, Consultant Pathologist, NHS Lothian, Department of Pathology, 
Western General Hospital, Edinburgh, Scotland, UK.  
Martin L Miller, Group Leader, Cancer Research UK Cambridge Institute, University 
of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge UK 
Alejandro Jiménez-Sánchez, Cancer Research UK Cambridge Institute, University 
of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge UK 
Roy Rabbie, Clinical Research Fellow, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge, UK 
 2
Mamunar Rashid, Senior Computational Biologist, Wellcome Trust Sanger Institute, 
Hinxton, Cambridge, UK 
Jack Satsangi, Professor of Gastroenterology, Centre for Genomic and 
Experimental Medicine, University of Edinburgh, Edinburgh, Scotland, UK 
David J Adams, Senior Group Leader, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge, UK 
Mark J Arends, Professor of Pathology, Division of Pathology, Centre for 
Comparative Pathology, Cancer Research UK Edinburgh Centre, Institute of 
Genetics & Molecular Medicine, Western General Hospital, University of Edinburgh, 
Edinburgh, Scotland, UK 
α The first two authors contributed equally 
 
Running Title predictive biomarkers in IBD-associated colorectal cancers 





This work was supported by the European Research Council Combat Cancer 
Program, Cancer Research UK and the Wellcome Trust. 
SD acknowledges the financial support of NHS Research Scotland (NRS), through 
NHS Lothian. 
AJS was supported by a doctoral fellowship from the Cancer Research UK 




Dr Shahida Din, Consultant Gastroenterologist, Gastrointestinal Unit, Level 1 Anne 
Ferguson Building, Western General Hospital, Crewe Road South, Edinburgh, 
Scotland, UK, EH4 2XU. 
Email: sdin@ed.ac.uk  
Contact telephone: 00 44 (0) 7912092918 
 
Conflict of Interest disclosures: 
The authors declare no potential conflicts of interest.  
 
Total Word Count 4917 
Main Tables 2 
Main Figures 5 
 
Abbreviations 
CD   Crohn’s disease 
 4
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Statement of Translational Relevance 
There is an urgent need to identify predictive biomarkers in inflammatory bowel 
disease-associated colorectal cancers (IBD-CRCs) to individualise the current 
prevention, surveillance and treatment programmes. This analysis demonstrates that 
proximal IBD-CRCs have high mutational rates associated with defects in MMR 
(MLH1 loss) and DNA POLE proofreading function. Hypermutation is associated with 
a predicted higher neo-epitope load, which could be exploited using 
immunotherapies in selected patients with hypermutated IBD-CRCs. Prospective 
studies are required to determine whether analysis for loss of MLH1 in surveillance 
colonic biopsies could discriminate those at increased risk of developing CRC, 
permitting a more targeted approach for cancer treatment and surveillance. The 
identification of driver genes in hypermutated IBD-CRCs could also be used to 
develop therapeutic agents targeting the corresponding molecular pathways. Our 
comprehensive analysis of the mutational landscape of IBD-CRCs has revealed 




Purpose: Inflammatory bowel disease-associated colorectal cancers (IBD-CRCs) are 
associated with a higher mortality than sporadic colorectal cancers. The poorly 
defined molecular pathogenesis of IBD-CRCs limits development of effective 
prevention, detection and treatment strategies. We aimed to identify biomarkers 
using whole exome sequencing of IBD-CRCs to guide individualised management.  
Experimental Design: Whole-exome sequencing was performed on 34 formalin-
fixed paraffin-embedded primary IBD-CRCs and 31 matched normal lymph nodes. 
Computational methods were used to identify somatic point mutations, small 
insertions and deletions, mutational signatures, and somatic copy number alterations.  
Mismatch repair status was examined.  
Results: Hypermutation was observed in 27% of IBD-CRCs. All hypermutated 
cancers were from the proximal colon; all but 1 of the cancers with hypermutation 
had defective mismatch repair or somatic mutations in the proofreading domain of 
DNA POLE. Hypermutated IBD-CRCs had increased numbers of predicted neo-
epitopes, which could be exploited using immunotherapy. We identified 6 distinct 
mutation signatures in IBD-CRCs, 3 of which corresponded with known mechanisms 
of mutagenesis. Driver genes were also identified. 
Conclusions: IBD-CRCs should be evaluated for hypermutation and defective 
mismatch repair to identify patients with a higher neo-epitope load who may benefit 
from immunotherapies. Prospective trials are required to determine whether 
immunohistochemistry to detect loss of MLH1 expression in dysplastic colonic tissue 
could identify patients at increased risk of developing IBD-CRC. We identified 
mutations in genes in IBD-CRCs with hypermutation that might be targeted 
therapeutically. These approaches would complement and individualise surveillance 




Inflammatory bowel disease associated colorectal cancer (IBD-CRC) is an 
aggressive complication of chronic inflammation accounting for 10-15% of deaths 
from IBD. IBD-CRC patients are younger and have a higher mortality than those with 
sporadic colorectal cancer (1). IBD-CRC arises diffusely in chronically inflamed 
epithelium via low-grade dysplasia evolving to high-grade dysplasia and eventually 
adenocarcinoma, although it may also arise without these preceding changes. 
Technological advances in endoscopy have improved the ability to discriminate 
between normal and pre-cancerous mucosa (1), however, a third of cancers arise in 
the interval between scheduled colonoscopies, suggesting poor efficacy of 
surveillance programmes (2). Colonoscopy-directed mucosal samples are analysed 
for the presence of dysplasia, which remains the gold standard for predicting future 
cancer risk in IBD when reported by an expert gastrointestinal pathologist.  
The poorly defined molecular and genetic pathogenesis of IBD-CRC impairs our 
ability to detect and treat colorectal cancer effectively. There is an urgent need to 
identify biomarkers to improve early detection of colorectal cancer and guide 
individualised therapy (2).  
We elected to study primary IBD-CRC since molecular changes identified in the 
resected cancer specimen are most likely to represent biomarkers of cancer 
development.  We characterised the hypermutator status of the cancers, defined the 
mutational signatures and underlying biological processes, and explored the potential 
clinical translation of this work with respect to immune therapy, and improving current 




MATERIALS and METHODS 
Ethical Approval and Case Identification 
The study was approved by the Lothian NHS Research Scotland Human Annotated 
BioResource, which is an NHS Health Research Authority Ethics Committee-
approved Research Tissue Bank (www.hra.nhs.uk; 15/ES/0094) for the use off 
human tissue surplus to diagnostic requirements. The study was conducted in 
accordance with the Declaration of Helsinki and the guidance from the Human Tissue 
Authority on the use of human tissue from diagnostic archives. The Lothian 
(Edinburgh, UK) pathology database was searched for IBD-CRCs using the terms 
inflammatory bowel disease, Crohn’s disease, ulcerative colitis, colon cancer, 
colorectal and rectal cancer between 1990 and 2011 by the Tissue Bank appointed 
pathologist and provided the anonymised tissue samples with linked clinical data. 
Two independent expert GI pathologists (MJA and CJB) and a specialist IBD 
Consultant Physician (SD) verified the IBD-CRCs following careful review of the 
patient’s anonymised medical records, the histopathological evidence for IBD in 
previous colonic samples and in the IBD-CRC resection specimen.  
Cases were only included from patients with a previous histopathological diagnosis of 
IBD and where evidence of IBD in the resected colonic specimen was confirmed by 
both GI specialist pathologists (CJB and MJA) independently. Sporadic adenomas 
and colorectal cancers which arose in an area of the colon without prior evidence of 
IBD in that colonic area were excluded. For each case we have clear 
histopathological evidence of pre-existing IBD at each tumour site and have 
confirmed that we have selected IBD-associated colorectal cancers. 
Formalin fixed paraffin embedded (FFPE) cancer and uninvolved normal lymph node 
blocks, removed at the time of surgery, were sectioned, H&E stained and used for 
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further analysis. In total 31 cases (15 Crohn’s Disease (CD): 16 Ulcerative Colitis 
(UC)) with 34 cancers were used in this study.  
 
Clinical Phenotype Data: Statistical Analysis 
The ‘survival’ package within the R software environment (3) was used to generate 
the Kaplan-Meier survival curves and perform statistical analyses. Categorical clinical 
phenotype data was analyzed using the Two-tailed Fisher’s exact test; a P-value of 
<0.05 was considered significant. No survival data was available for case 2L 
(hypermutator) which was excluded from the survival analysis. Cases 15G1 and 
15G2 were considered as one case for the purpose of statistical comparison, as they 
appear to originate from the same precursor clone. 
 
Sequencing Data Generation, Processing and Analyses 
Nucleic acids were extracted using Qiagen Allprep FFPE DNA extraction kits, and 
DNA/RNA was quantified using Agilent GeneChips. For WES, DNA was captured 
using the Agilent SureSelectXT Human All Exon V5 platform following the 
manufacturer’s protocol. Sequencing was performed using the Illumina HiSeq 2000 
platform at the Wellcome Trust Sanger Institute. Raw paired-end sequencing reads 
(75bp) were aligned and a modified version of the reference genome which includes 
the GRCh37 primary assembly and additional human contigs and viral sequences 
that reduce the number of reads erroneously mapped to the primary assembly. 
Further details on data processing, data quality assessment and sequence alignment 
are available in the Supplementary Materials and Methods. Somatic point mutations 
and small insertions and/or deletions (InDels) were identified by comparing cancer 
and matched normal samples using MuTect (v1.1.7) (4) and Strelka (v1.0.14) (5), 
respectively. BCFtools (v1.3) (6) was used to identify variants in each patient’s 
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germline (normal lymph nodes) relative to the human reference genome described 
above. The Ensembl Variant Effect Predictor (7) software was used to predict the 
effect of each variant on protein sequences, and the clinical significance of the 
changes was predicted by comparison to variants in the ClinVar database (release 
date 2016-05-31). For genes with multiple transcripts, we report the effect of the 
variant on the protein derived from the canonical transcript as annotated in Ensembl 
release 81 for GRCh37 (Supplementary Table S7; Supplementary Materials and 
Methods). We also provide the predicted effect on all transcripts in Supplementary 
Table S8. The Sequenza software package (version 2.1.2) (8) was used to identify 
somatic copy number alterations. For the non-hypermutator cases, MutSigCV 
(version 1.4) (9), which identifies significantly mutated genes, and dNdScv (10), 
which identifies genes under positive selection in cancer, were used to identify driver 
genes. For the hypermutator cases, microsatellite InDels were excluded from 
analysis with MutSigCV. The microsatellite InDels were analysed with a modified 
version of MSMutSig (11) obtained from the author, along with required input files. In 
dNdScv, which is able to analyze both the SNV and InDel mutations together in both 
hypermutator and non-hypermutator cohorts, two InDel models are available; one 
model considers the total number of InDel mutations per gene, and the other model 
considers unique InDel sites per gene (the “unique-sites model”). For the 
hypermutator cohort, dNdScv was run using both models, and the results were 
compared. Only the “unique-sites” model was used for the non-hypermutator cohort. 
Restricted hypothesis testing was performed on the results from dNdScv, using 
known cancer genes from the Cancer Gene Census version 81 (12). Further details 
are available in the Supplementary Materials and Methods. Mutation signatures were 
identified with the Bioconductor package SomaticSignatures (version 2.6.0) (13) 
using the non-negative matrix factorization (NMF) algorithm. Details of software 
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parameters, databases used, variant annotation, variant filtering, validation and the 
identification of driver genes are available in the Supplementary Materials and 
Methods. 
 
HLA Typing and Neo-epitope Predictions 
Human leukocyte antigen (HLA)-I 4-digit typing was performed using the OptiType 
1.0 algorithm and neo-epitopes from missense mutations were predicted by mapping 
the corresponding protein sequences to the human proteome database (version 
GRCh37.74). Neo-epitopes with a relative percentile rank ≤ 1% for each HLA-I allele 
were considered binders (additional details are provided in Supplementary Materials 
and Methods).  
 
Mismatch Repair Immunohistochemistry  
Immunohistochemistry for MLH1, MSH2, MSH6 and PMS2 was undertaken on a 
cancer tissue microarray and staining was independently scored by two pathologists 
(MJA and AO). Discordant scores were resolved by staining whole tissue sections 
with additional MLH1, MSH2, MSH6 and/or PMS2 antibodies. 
 
MLH1 Promoter Methylation Analysis 
MLH1 promoter methylation was analysed using the EZ DNA Methylation Kit Gold 
(Zymo Research). Cases from patient 32N failed methylation analyses.  







To identify biomarkers associated with IBD-CRC, WES was performed on 34 IBD-
CRCs and matched normal lymph node pairs. Twenty-nine patients had one cancer, 
one patient had three primary cancers separated anatomically (32N) and one patient 
had two cancers in close proximity to each other (15G) (Supplementary Table S1). 
WES yielded between 45- and 90-fold coverage of the cancer samples and 26- and 
93-fold coverage of the normal lymph node samples (Supplementary Fig. 1). When 
considering protein coding and splice site mutations only, the cancers from 32N had 
only 6 mutations common to at least 2 of the 3 cancers, while the two cancers from 
15G had over 2345 common mutations (22% of the total mutant positions in these 
cancers).  
 
Somatic Mutation Rates in IBD-CRC  
Somatic point mutations and InDels were identified by comparing exome sequences 
from cancer tissue with those from uninvolved lymph nodes removed at the time of 
surgery (Supplementary Tables S7 - S8).The 34 cancers were divided into two 
groups based on distinct somatic mutation rates. There were 24 non-hypermutator 
cancers with 2.0-7.0 mutations/Mb, and 10 hypermutator cancers with 32.6-171.3 
mutations/Mb (Fig. 1A and Table 1). Two of the 10 cases, 15G1 and 15G2, have a 
somatic mutation burden greater than 100 mutations/Mb and could thus be defined 
as ultra-hypermutators. 
The proportion of hypermutators in our IBD-CRC data set was 27%, or 9/33 (cases 
15G1 and 15G2 were counted once, since they appear to originate from the same 
precursor clone) and was not significantly higher than the 16% present in a cohort of 
382 sporadic CRCs downloaded from The Cancer Genome Atlas (TCGA) Data Portal 
(see Supplementary Materials and Methods) (right sided binomial test, P=.07), nor 
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the 28% observed in a larger cohort of 619 sporadic CRCs from Giannakis et al. 
(binomial test, P=1) (14). The hypermutator cases had elevated levels of both single 
nucleotide variants (SNVs) and InDels, with the exception of cases 15G1, 15G2 and 
6J, which have similar InDel mutation rates to the non-hypermutator cases (Fig. 1A). 
The median age at diagnosis was not significantly different between the 
hypermutators (median 66.2 years; IQR 57.4-78.1 years) and non-hypermutators 
(median 65.8 years; IQR 51.0-77.0 years).  
Overall, there was a significant survival difference between the patients with 
hypermutator cancers and those with non-hypermutator cancers (log rank test, 
P=.04), with the estimated 10-year survival being 75% in the former group as 
compared with 36% in the latter (Fig. 1B). However, it is likely that additional factors 
other than mutator status including stage and age influenced patient survival 
although we were unable to measure the affects of these variables due to the small 
sample size. 
Strikingly, the hypermutator cancers were all located in the proximal colon and none 
in the distal colon (two-tailed Fisher’s exact test, P=.004) (Fig. 2).  
 
Mismatch Repair Abnormalities 
To characterise the difference in mutational rates, the cancers were analysed for 
genetic aberrations associated with dMMR. Seven out of the ten hypermutator 
cancers had a high frequency of InDels (Fig. 1A), which is indicative of MSI, and 
showed loss of expression of MLH1 and its heterodimeric binding partner PMS2 (Fig. 
2; Supplementary Fig. 2). Loss of MLH1 protein expression results in dMMR, leading 
to increased somatic substitution and susceptibility to cancer (15). Loss of MLH1 
expression can be explained by MLH1 promoter hypermethylation in 5 of these 7 
cancers (Fig. 2; Supplementary Fig. S3). One of the two remaining cancers (33W), 
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had a somatic nonsense mutation within the ATPase domain (R100*) of the MLH1 
gene, resulting in a truncated protein with a predicted loss of function. We did not find 
other coding mutations that would cause MLH1 to be biallelically inactivated in case 
33W. We did not detect any point or InDel mutations in MLH1 in the germline or 
tumour in case 28E, nor epigenetic silencing by promoter hypermethylation that could 
explain the loss of MHL1 expression in this case. The normal expression of MLH1 
and low level of somatic InDels in the remaining 3 hypermutator cancers, 15G1, 
15G2, and 6J, point to alternative mechanisms leading to hypermutation. In contrast, 
loss of expression, promoter hypermethylation and non-silent somatic mutations 
were not observed in MLH1 in the non-hypermutator cases (Fig. 2; Supplementary 
Table S2B).  
 
Mutations in DNA Polymerase Proof-reading Domains 
During DNA replication, DNA fidelity is maintained by the proof-reading function of 
DNA polymerases. Germline mutations in the exonuclease proof-reading domains of 
the DNA polymerases POLD1 (codons 245-571) and POLE (codons 223-517) have 
been shown to predispose to the development of hypermutated microsatellite stable 
(MSS) sporadic colorectal cancer (16). Non-silent somatic mutations in POLE and 
POLD1 were identified in 4 and 7 of the hypermutator cancers, respectively (Fig. 2; 
Supplementary Table S2A). Two shared somatic POLE mutations (P286R and 
F348S) affected the exonuclease proof-reading domain in cases 15G1 and 15G2, 
which were two adjacent cancers (adenocarcinoma and squamous cell carcinoma) in 
the same patient (Fig. 1A; Fig. 2).  
No frameshift or non-silent somatic POLE or POLD1 point mutations were identified 
in the non-hypermutator cancers. 
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The mechanism of hypermutation in case 6J remains undefined. Case 6J was an 
adenocarcinoma from a patient with a 20 year history of colonic Crohn’s disease and 
autoimmune liver disease for which she received potent immunosuppression 
(prednisolone, tacrolimus and azathioprine) throughout this period. This patient had 4 
basal and 2 squamous cell carcinomas of skin removed but did not have any 
frameshift or non-silent somatic or germline point mutations in PTCH1, excluding 
Gorlin syndrome as a contributing factor to the underlying cancer predisposition (17). 
In addition, germline mutations that could explain the hypermutator phenotype were 
not found in other DNA repair genes including those involved in nucleotide and base 
excision. It is possible that the continuous, prolonged immunosuppression in this 
patient has altered the immune cancer response resulting in both colonic and 
multiple skin cancers. 
 
Mutational Signatures in IBD-CRC 
It has been demonstrated that different mutational processes in cancers generate 
specific patterns of mutation, or ‘signatures’, with 30 distinct signatures identified thus 
far by Alexandrov et al. (18). The overall mutational spectrum our IBD-CRC cohort 
was very similar to the spectra derived from cohorts of sporadic CRCs from 
Giannakis et al. (14) (cosine similarity=.87) and from TCGA Data Portal (cosine 
similarity=.91) (Fig. 3A; Supplementary Materials and Methods). Six distinct 
signatures, designated A-F, were extracted from the catalogue of IBD-CRC somatic 
mutations (Fig. 3B) and corresponded well to Alexandrov Signatures 10, 1, 13/2, 17, 
6 and 5, respectively, with cosine similarities ranging from .82 to .97 (Fig. 2 lower 
panel; Supplementary Table S3). Some of the signatures have been associated with 
specific mutational mechanisms (18). Of particular note, are IBD-CRC Signature A 
(Alexandrov Signature 10/POLE) that was predominant in the hypermutator cancers 
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with DNA POLE mutations (15G1 and 15G2); and IBD-CRC Signature E (Alexandrov 
Signature 6/dMMR and MSI) that was predominant in the 7 hypermutator cancers 
which had loss of expression of the MLH1 protein (Fig. 2). IBD-CRC Signature C 
(Alexandrov Signature 13 and 2/AID/APOBEC) is the major contributor in case 21M, 
however as we our analysis is limited to the exome regions only, we have no 
evidence of AID/APOBEC activation in this case. Transcriptional upregulation of 
APOBEC3B is commonly found in bladder, cervical, lung, head/neck and breast 
cancers with kataegis (18),  however, we did not find evidence of kataegis in case 
21M (Supplementary Fig. S4). It has been hypothesised that one cause of 
APOBEC3B upregulation may be infection by viruses, including Human 
Papillomavirus (HPV) (19). We did not find HPV DNA associated with case 21M, 
however, since whole-exome sequencing was used in this study, any viral sequence 
present would be excluded unless it has integrated into the genome in the targeted 
sequences.   
Although Alexandrov signatures 2 and 13 have not yet been identified in CRC, an 
APOBEC mutation pattern has been found, using different methods, in a variety of 
cancer types including whole-genome sequenced sporadic CRCs (20). Signatures 1, 
5, 6 and 10 have previously been found in sporadic colorectal cancers (18) and 
signature 17 has been identified in MSS CRC (21). Taken together, these results 
indicate that the mutational mechanisms in IBD-CRC and sporadic CRC are similar, 
although a much larger IBD-CRC cohort and whole-genome sequencing may reveal 
additional or novel signatures.  
 
Recently, a signature attributed to the persistence of 8-oxoguanine G>T/C>A 
mismatches due to biallelic inactivation of MUTYH has been identified in MUTYH-
associated polyposis (MAP) CRCs (22). Unsurprisingly, we did not find this signature 
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in our IBD-CRCs as our cases did not have a history of MAP nor any germline non-
silent or splice site point or InDel mutations in MUTYH other than common SNPs. We 
did not discover a novel inflammation-associated mutational signature in our cohort. 
Similarly, others have not found an inflammation-signature common to chronic 
inflammatory-associated gastrointestinal cancers (such as Barrett’s oesaphagus) 
(23). Rather, epithelial regeneration and the subsequent cumulative effect of chronic 
inflammation-associated damage appears to be a major mechanism of promoting 
carcinogenesis in IBD (24).  
 
Driver Genes in IBD-CRC 
To identify driver genes in non-hypermutator IBD-CRC, we used MutSigCV (9) to 
identify significantly mutated genes, and dNdScv to find genes under positive 
selection in cancer (10) (Methods and Supplementary Materials and Methods). In our 
24 cases, TP53, PIK3CA, APC, and KRAS were identified as driver genes (FDR-
adjusted P-value, or q<.10) (Fig. 4A), all of which are also driver genes in sporadic 
CRC (25). As observed in sporadic CRC (25), significantly more non-hypermutator 
cancers had non-silent somatic mutations in TP53 than the hypermutator cancers 
(79% vs. 33%; Two-tailed Fisher’s exact test, P=.03) (Table 2). 
In the hypermutator cases, no driver genes were identified using MutSigCV (9) or 
MSMutsig (11), due to small sample size. When using dNdScv (10), followed by 
restricted hypothesis testing with a list of known cancer genes from the Cancer Gene 
Census (version 81) (12), KRAS (q=.03) was identified as a driver gene in the 
hypermutator cohort, in which 3 of the 4 cases with KRAS mutations are  p.G12D 
(Fig. 4A).  Importantly, this analysis also identified hotspot InDel mutations in RPL22 
(p.K15fs; q=.001), ACVR2A (p.K437fs; q=.03) and RNF43 (p.G659fs; q=.1) (Fig. 4A; 
Supplementary Materials and Methods). The same ACVR2A and RNF43 mutations 
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have previously been identified as driver events in a much larger cohort of sporadic 
CRC (11), and while they may represent driver events in IBD-CRC, they could also 
be genomic sites that are particularly prone to mutation. A much larger cohort of MSI 
IBC-CRCs would be required to confirm these as driver events. As reported for 
sporadic CRCs (26), we find enrichment of RNF43 mutations in MSI cases, and 
mutual exclusivity of RNF43 truncating mutations (which includes frameshift InDels, 
nonsense mutations and splice site mutations) with APC truncating mutations in our 
IBD-CRC cohort (Fig. 4A).   
Several of the genes we identified are clinically actionable. For example, tumours 
with RNF43 mutations are sensitive to porcupine inhibitors (27). In the same way 
RPL22 mutant cancers may be susceptible to MDM2-p53 pathway compounds (28). 
Notably, the same RPL22 p.K15fs hotspot mutation we identified in our IBD-CRC 
cohort has been frequently found in endometrial, gastric and colorectal cancers (28). 
 
Somatic IDH1 R132 Mutations 
A potentially targetable IDH1 hotspot mutation at R132, which was mutated in 11% 
(5/47) of IBD-CRCs and only in CD-associated CRCs, was previously reported by 
Yaeger et al. (29). In our cohort, one IDH1 R132C mutation was present in UC-
associated CRC case 32N3. The observed frequency here is not significantly 
different than that of Yaeger et al. (29) (Chi squared test, P=.21).  We note, however, 
that the median 17-fold coverage (range 9-36-fold in the tumour samples) at this site 
was lower than the whole-exome median of 70-fold, as this mutation is only 20bp 





Somatic Copy Number Alterations in IBD-CRC 
As previously observed with sporadic CRC (30), somatic copy number alterations 
(SCNAs) in IBD-CRCs were significantly more prevalent (one-tailed Student’s t-test 
P=.001) in the non-hypermutator cases compared with hypermutator cases 
(Supplementary Fig. S5; Supplementary Table S6).  
Robles et al. (31) reported 15 focal copy number gains, 8 of which were observed in 
more than one tumour and Shivakumar et al. (32) reported 26 focal SCNAs in pooled 
IBD-associated dysplastic and carcinoma biopsy samples. Focal SCNAs common to 
our IBD-CRC cohort and these studies are gains in 12p13.33-12p13.31, 22q11.21, 
4p16.3, 8q24.3, 10q26, 13q12, 20q11.23 and 20q13; however, none were common 
to all three. 
We compared the frequency of predicted chromosome arm-level SCNAs to recurrent 
SCNAs found by Sheffer et al. (33), and to SCNAs identified by TCGA (25) (Fig. 4B; 
Supplementary Table S6). Our novel data demonstrate that the frequencies of 
specific arm-level SCNAs in IBD-CRC broadly concurs with those found in sporadic 
CRC (25, 33).  
 
Germline Variants in IBD Patients  
Colorectal cancer affects up to 2.5% of the patients who suffer from IBD (1), and 
germline variations conferring cancer susceptibility have been poorly described in 
this population of patients. We examined the germlines of our cohort for variants in 
genes implicated in susceptibility to colorectal cancer (Supplementary Tables S4 - 
S5). The CHEK2 frameshift mutation at T367 (c.1100delC; rs555607708), in the 
germline of case 15N, is known to predispose to breast cancer, but association with 
colon cancer has not been resolved (34). The R242H mutation in SDHB 
(rs74315368) in case 3Q has been characterized in paragangliomas (35) but not, to 
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our knowledge, in colon cancer. The remaining germline variants we have reported in 
Supplementary Table S5 are in genes known to be associated with increased risk of 
CRC, however, they have unknown or mixed reported clinical significance and 
currently we are unable to clarify as to whether these variants confer a predisposition 
to colorectal cancer in the setting of chronic inflammation. 
 
Neo-epitope and Immune Infiltrate Analysis 
Non-synonymous somatic mutations in cancer can generate novel antigens, (neo-
epitopes) that can be exploited in cancer immunotherapy. The number of predicted 
neo-epitopes is expected to be directly proportional to the mutational load of cancers 
(36). As expected, the IBD-CRC hypermutator cancers generated the largest number 
of HLA Class I neo-epitopes, and were significantly higher than the number found in 
non-hypermutators (one-tailed Student’s t-test, P=.004) (Fig. 5). Similar to our study 
the neo-epitope load was higher in sporadic CRC with dMMR/MSI-high status, than 
in pMMR/MSS tumours, and notably, they responded favourably to PD1 blockade 
(14). IBD is characterized by a dysregulated immune response and many therapeutic 
modalities targeting inflammation are directed at cytokines. Analysis of the cytokine 
gene immune expression profile demonstrated that overall the cytokine gene 
expression profile was similar in the hypermutator IBD-CRCs and the non-
hypermutator IBD-CRCs (Supplementary Fig. S6), although this analysis was limited 




We have undertaken a comprehensive analysis of 34 IBD-CRCs from 31 patients 
using WES. Hypermutator cancers were observed in both our study and Robles et al. 
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(31) and the mutational rates were within range of the larger TCGA sporadic CRC 
cohort (25).  
In sporadic and hereditary colorectal cancers, the hypermutator phenotype is most 
frequent in cancers of the right (proximal) colon (25) . In this study, we observed a 
strong association between CD-associated CRCs occurring in the proximal colon 
(Two-tailed Fisher’s exact test, P=.03) and the hypermutator phenotype (Two-tailed 
Fisher’s exact test, P=.05. Long standing, extensive colonic CD has been shown to 
be associated with proximal cancers (37) and we have clear histopathological 
evidence of pre-existing IBD at each tumour site, more than half of which were in the 
proximal colon. Similar to previous studies of IBD-CRC (38) a higher proportion of 
UC-associated CRCs occurred in the left colon (Fig. 2) when compared with CD-
associated CRCs (Two-tailed Fisher’s exact test, P=.03) . 
Previous studies have reported a variable frequency of MLH1 promoter 
hypermethylation and loss of expression of MLH1 in IBD-CRCs (39). The frequency 
of MLH1 promoter methylation in our series may be associated with the more 
advanced age at time of IBD-CRC diagnosis, although it remains lower than that of 
sporadic MSI-high CRC with CpG (MLH1) hypermethylation (40). Lennerz et al. (39) 
have exclusively studied CRC complicating Crohn’s colitis and described the median 
age of cancer diagnosis to be 58 years (range 34–77) which is also slightly higher 
than that conventionally reported for IBD-CRCs. In addition to our strict inclusion 
criteria, and similar to previous studies (39), the mutation analysis identified a single 
BRAF V600E mutation in one hypermutator IBD-CRC (Fig. 2) confirming that these 
cancers are unlikely to be sporadic in nature.  
BRAF V600E mutations occur in the majority (>85%) of hypermethylated sporadic 
MSI high CRCs (25) and are therefore established in diagnostic algorithms to 
differentiate between sporadic and familial Lynch Syndrome cases of colorectal 
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cancer (41). Notably, we did not identify germline mutations in genes such as MLH1, 
MSH2, APC, and MUTYH that predispose to the development of CRC in our IBD-
CRC cohort.  Although the  proportion of hypermutator cancers in our cohort was not 
significantly different than that in sporadic CRC, these differential mutations 
distinguish our hypermutated IBD-CRC cohort from hypermutated sporadic and 
familial forms of CRC.  
 
The effect of dMMR/MSI on survival outcomes in IBD-CRC has not been reported. A 
recent meta analysis of 20 studies including 571,278 patients by Reynolds and 
colleagues (42) has reported that IBD-CRC does not affect the overall 5 year survival 
compared with sporadic CRC without any adjustment for molecular subtypes. In our 
series, the hypermutator IBD-CRCs (which included 2 MSS hypermutators 15G and 
6J) had a significantly better survival compared with non-hypermutator IBD-CRCs. 
The increased survival of sporadic MSI cancers (43) is comparable to the data 
presented here for IBD-CRCs. The improved survival of early stage sporadic 
dMMR/MSI cancers is postulated to be mediated by (anti-) tumour infiltrating 
lymphocytes (TILs) in response to the neo-epitopes generated by the high mutational 
rate. Immune blockade therapies targeting immune checkpoints and enhancing the 
anti-TIL response are currently being used in various cancers including CRC (44). In 
our series, the hypermutator IBD-CRCs had a higher predicted neo-epitope load but 
we were unable to identify any obvious differences in the immune related gene 
expression profile. This is unsurprising as our samples had been enriched for cancer-
containing cells and not the adjacent immune rich stromal compartment. Molecular 
phenotyping of all colorectal cancers for targeted therapy is a compelling reason for 
universal screening for dMMR . Of note, the United States Food and Drug 
Administration has approved Pembrolizumab (targeting the programmed cell death 1 
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receptor) for the treatment of all unresectable or metastatic MSI-H/dMMR tumours 
that have progressed after initial treatment (45). Immune checkpoint blockade has 
been associated with immune-mediated colitis and this is particularly relevant for 
patients with co-existing inflammatory bowel disease (46). Although our results 
require validation in a randomized prospective cohort, it is exciting to postulate that 
immune blockade therapies may be useful adjuncts in treating patients with dMMR 
(and/or hypermutator phenotype) associated IBD-CRC that have undergone a total 
colectomy as part of their treatment programme, negating the risk of immunotherapy 
mediated colitis. Importantly, immune therapies should be used with caution or 
avoided in IBD-CRC patients who have undergone a partial colectomy or those with 
Stage IV disease with an intact colon as it can aggravate the underlying colitis (47).  
 
To date, we have not been able to use genetic or molecular markers to improve the 
detection or treatment of IBD-CRC. In 2009, a specialist committee in the United 
States of America recommended universal screening for Lynch syndrome in all newly 
diagnosed colorectal cancers (48) and this has not been adopted for several reasons 
including financial, technical, ethical and health economical limitations. In the United 
Kingdom, the National Institute for Health and Care Excellence (NICE) is advocating 
use of mismatch repair immunohistochemistry on all colorectal cancers (including 
IBD cases) to detect Lynch syndrome (41). A cost effective analysis limited to early 
onset colorectal cancers suggests that this would be economically viable assuming 
that all of the necessary subsequent health interventions are fully implemented to 
reduce cancer mortality and morbidity (49). Our data supports this recommendation 
to detect dMMR in IBD-CRC, but not necessarily to detect Lynch syndrome as we did 
not identify any known clinically significant pathogenic germline mutations in MMR 
genes in this IBD-CRC cohort. Whilst these important issues are resolved our data 
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can be used to support the rational for universal testing in IBD-CRCs to profile 
tumours for the use of targeted therapies, which is not routinely undertaken at all 
institutions,  
The immunohistochemical analysis of TP53 protein has not been widely accepted to 
aid in the discrimination between dysplastic and inflamed colonic epithelium. 
Prospective studies are required to determine whether analyzing for TP53 
abnormalities and loss of expression of MLH1 together, in colonic biopsies with 
potentially dysplastic epithelium, could aid in the evaluation of those at highest risk of 
developing CRC, similar to the molecular profiling used in gastric cancer (50).  
 
Our retrospective study has inherent limitations and the small sample size may result 
in a reporting bias. Notwithstanding these issues, the power of next-generation 
sequencing technology has provided detailed information allowing clinically relevant 
statistical analyses to be undertaken. Future similar studies may discover many more 
similarities and differences between IBD-CRC and other types of CRC. 
 
CONCLUSION 
The categorisation of disease guides individualised therapeutic strategies and can 
predict the response to therapy and prognosis. Our analysis demonstrates that 
proximal IBD-CRCs have high mutational rates associated with defects in MMR and 
DNA POLE proof-reading function. This results in a predicted higher neo-epitope 
load, which could be exploited using immunotherapies. The hypermutator phenotype 
of this cohort is mostly associated with loss of MLH1 expression and this could be 
evaluated in colonic dysplastic lesions detected in IBD patients. The identification of 
driver genes in hypermutated IBD-CRCs can be used to develop therapeutic agents 
targeting the corresponding molecular pathways. In our series up to 90% of the 
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hypermutated IBD-CRCs have actionable mutations. These approaches would 
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TCGA(25) DIN ROBLES(31) 
Hypermutators >12 (728) 32.6-171.3 (56.2) 18.19-22.2 (N/A) 
Non-hypermutators 
<8.24 (58); 
Non-silent mutations only 
2.1-7.0 (3.1) 0.3-5.1 (1.3) 
 
Mutational rates (mutations/Mb) from the whole-exome sequence analysis of TCGA sporadic CRC 
cohort (25) and IBD-CRCs from this study and Robles et al. (31) in the hypermutator and non-
hypermutator cancers. Numbers in parentheses are median mutation rates. Two hypermutators were 
present in the Robles cohort. The rates provided include total mutations with the exception of the 
median mutation rate of non-hypermutator cancers in the TCGA cohort. 
 
Table 2 Frequency of TP53, KRAS and APC mutations in IBD-CRC and sporadic CRC. 
 
GENE TCGA HM(25) TCGA NHM(25) DIN HM DIN NHM ROBLES NHM(31) 
TP53 20%* 60%* 33%* 79%* 63% 
KRAS 30% 43% 44% 25% 20% 
APC 51%* 81%* 33% 29% 13% 
PIK3CA 13% 23% 56% 29% 10% 
 
Mutational frequencies from the whole-exome sequence analysis of TCGA sporadic CRC cohort (25) 
and IBD-CRCs from this study and Robles et al. (31) in hypermutator (HM) and non-hypermutator 
(NHM) cancers. 





Figure 1: Somatic mutational rates and survival analysis of IBD-CRC. 
(A). Mutational frequency in each of the 34 IBD-CRCs ordered by overall mutation 
rate. There is a clear separation between the 10 hypermutator cancers and the 24 
non-hypermutator cancers. With the exception of 15G1, 15G2, and 6J, the 
hypermutator cancers showed elevated mutation rates of both SNVs and InDels. No 
InDels were found in the exome of 21M. (B) Kaplan-Meier plot of overall survival 
stratified by cancer mutator phenotype. Patients with hypermutators cancers had 
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increased survival compared with patients with non-hypermutator cancers (log rank 
test, P=.04). 
 
Figure 2: Clinical and genetic characteristics of the IBD-CRC. 
Top panel: Mutational rate of each cancer case ordered by tumour site and mutation 
rate. The red line segregates the proximal and distal bowel cancers. Second panel: 
Tumour site, Dukes’ stage, cancer type, underlying IBD, immunohistochemical 
testing of MLH1 (MLH1 IHC) and promoter methylation status of MLH1 (MLH1 Pr-M). 
Third panel: selected genes and somatic nonsense, non-silent and InDel mutations. 
The colours indicate the predicted effect of the mutation on the protein sequence, 
and the number indicates the number of mutations with the same predicted effect. 
Note that in cases where a gene has multiple mutations with different predicted 
effects, only the effect type with the highest priority will be shown.  Further details are 
in the Supplementary Methods and Materials. The complete list of mutations and 
their effects is in Supplementary Tables S2A - S2B. Lower panel: Contribution of 
signatures of mutational processes (A-F) in each cancer case. Each signature A-F 
corresponds to a signature identified by Alexandrov et al. (Signatures 10, 1, 13/2, 17, 
6 and 5, respectively) with cosine similarities ranging from 0.82 to 0.97 
(Supplementary Table S3). 
 
Figure 3: Signatures of mutational processes in IBD-CRC. 
 (A). The somatic mutation spectra of the IBD-CRC and sporadic CRC datasets are 
represented by each of the six possible substitution types, C>A, C>G, C>T, T>A, 
T>C, T>G (including their reverse complements) in the context of their immediate 5’ 
and 3’ flanking bases, giving 96 possible motif combinations. For each substitution 
type, the 16 motifs are listed in order from left to right by the 5’ flanking base (A, C, G, 
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then T), then by the 3’ flanking base (A, C, G, then T). The IBD-CRC panel shows the 
mutation spectrum for 34 IBD-associated colorectal cancers; the CRC (TGCA) panel 
shows the mutation spectrum for 115 colon adenocarcinomas and 267 rectum 
adenocarcinomas from downloaded from TCGA Data Portal, and the CRC 
(NHS/HPFS) panel show the mutation spectrum for a cohort of 619 CRCs from 
Giannakis et al. (14). (B) Six distinct mutation signatures (A-F) were extracted from 
IBD-CRCs and on comparison with the Alexandrov Signatures 1 to 30 (33) using 
cosine similarity (Supplementary Table S3), the correspondence is: Signature A and 
Signature 10 (POLE mutations); Signature B and Signature 1 (age/spontaneous 
deamination of 5-methylcyotosine); Signature C and Signature 13/2 (AID/APOBEC 
activation); Signature D and Signature 17 (unknown aetiology); Signature E and 
Signature 6 (mismatch repair deficiency and microsatellite instability); Signature F 
and Signature 5 (unknown aetiology; found in all cancer types). 
 
Figure 4: Hotspot microsatellite InDels, driver genes and recurrent somatic 
copy number alterations in IBD-CRC genomes.  
(A). Hotspot InDels and driver genes in IBD-CRC. Somatic SNVs and InDels were 
used to identify hotspot InDels and driver genes in hypermutator (n=9) and non-
hypermutator cancers (n=24). Because hypermutator case 15G1 and 15G2 were 
related, SNV and InDels were merged for this analysis. (B) Chromosome arm-level 
somatic copy number alterations. Shown are predicted SCNAs that cover at least 
90% of a chromosome arm (left panel), and the frequency of the SCNAs in IBD-CRC 
(this study), and in sporadic CRC studies by Sheffer et al. (33)  and TCGA (25) (right 
panel). Chromosome arms are listed in descending order of frequency in IBD-CRC. 
Grey boxes in the frequency columns indicate unknown values. IBD-CRC cases are 
ordered left to right by overall SNV and InDel mutation rate. Cases to the left of the 
dashed line are hypermutator cancers. 
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Figure 5: Predicted HLA Class I neo-epitopes in IBD-CRCs. 
The cancers with the highest mutational rates (hypermutators) generated the largest 
number of predicted HLA Class I neo-epitopes. 
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SUPPLEMENTARY MATERIALS AND METHODS 
 
Tumour Tissue Microarray 
Formalin fixed paraffin embedded (FFPE) tumour and uninvolved lymph node blocks 
were sectioned and H&E stained to select suitable areas for macro-dissection. Six 
mm cores were used for creation of the tumour microarray. 
 
DNA/RNA Extractions, Exome Sequencing and Data Processing 
Nucleic acids were extracted using Qiagen Allprep FFPE DNA extraction kits, and 
DNA/RNA was quantified using Agilent geneChips. 
 
For sequencing library generation, genomic DNA was fragmented for each tumour 
and normal sample. Enrichment for exome regions was performed using the Agilent 
SureSelectXT Human All Exon v5 platform following the manufacturer’s protocol. Six 
PCR cycles were performed for library preparation, and two PCR cycles were 
performed at the hybridization stage. Captured fragments were indexed and 
sequenced using the Illumina HiSeq 2000 platform at the Wellcome Trust Sanger 
Institute. Raw paired-end sequencing reads (75bp) were aligned to the reference 
genome hs37d5 (as used in Phase 3 of the 1000 Genome Project (1)), which 
includes the GRCh37 primary assembly and additional human contigs and viral 
sequences that reduce the number of reads erroneously mapped to the primary 
assembly. Alignments were performed using the ‘aln’ and ‘sampe’ algorithms of 
Burrow-Wheeler Aligner (BWA) software package (version 0.5.10) (2) to produce 
binary Sequence Alignment/Map (BAM) files (2). The option used for BWA ‘aln’ was ‘-
q 15’ and default parameters were used for ‘sampe’.  Base quality score recalibration 
(BSQR) and read realignment around known common InDels was performed using 
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tools from the Genome Analysis Tool Kit (GATK) (3) with default parameters.  SNPs 
from dbSNP build 135 (4) were used as known sites for BQSR, and known InDels as 
used by the 1000 Genomes Project (1) were used for realignment around InDels. All 
files were downloaded from the 1000 Genomes Project FTP site: 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/phase2_mapping_resour
ces/. Per sample, between 0.004% to 11% (median 1%) of reads were unmapped, 
and 16%-31% (median 22%) of reads were PCR duplicates. The average Phred 
scaled mapping quality ranged from 24-34 (median 30). PCR duplicates were flagged 
with Biobambam (version 0.0.188) function ‘bammarkduplicates’ (5), and removed 
from BAM files. Secondary read alignments were also removed, as were reads that 
failed Illumina chastity (purity) filtering. Upon visual inspection of read alignments, we 
discovered apparent chimeric PCR duplicates comprised of one read mate mapped 
to distant repeat elements, and these read pairs were also excluded from the BAM 
files for downstream analyses. Among all samples, the portion of reads mapping to 
exome bait regions plus 100 bp flanking sequence was 53%-77% (median 71%).  
Variant calling was not performed on reads aligning outside of these regions. 
Variants called at the BAP1 locus resulting from a contaminating plasmid were 
removed from all downstream analyses. 
 
All raw sequencing data is available from the European Genome-phenome Archive 
under accession number EGAS00001001129. 
 
Assessment of Deamination Artefacts 
To assess deamination artefacts, for each sample we generated plots of read depth 




















Artefacts from 5mC deamination (C>T/G>A) are typically observed at ~10% VAF and 
lower, at a wide range of read depths. We did not visualize an excess of C>T/G>A at 
these levels, however, as many of the samples appeared to have low cellularity (non-
C>T/G>A mutations with 10-20% VAF) it was visually difficult to estimate the level of 
5mC deamination artefacts. This also made filtering of mutation calls using a VAF 
cutoff (in addition to those already applied by the variant calling software) not 
practical since many true somatic mutations would be lost. To further evaluate 
deamination artefacts and false positives, we performed validation experiments, 
described below and in the “Validation of Somatic Variants” section.  
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From validation experiments using the Sequenom MassARRAY iPLEX genotyping 
platform, the overall false positive rate for the point mutations was estimated to be 
15% (see below). Approximately 68% (40/59) of the false positive point mutation calls 
were C>T or A>G. This makes up 16% (40/254) of the total C>T or A>G mutations 
with successful base calls from Sequenom MassARRAY iPLEX genotyping. The 
majority of these are likely artefacts from 5mC deamination. As the overall false 
positive rate is 15%, there will be a small effect on calculation of mutation rates and 
neo-epitope predictions; however, the effect is not large enough to change the main 
conclusions regarding mutator status and neo-epitope load. Artefacts resulting from 
5mC deamination occur in a specific context but in random genomic locations, and at 
low levels, would have little or no effect on the discovery of driver genes.  There is a 
known mutational signature associated with C>T/A>G substitutions originating from 
5mC deamination (Alexandrov signature 1), and these would be classified as such in 
the mutational signature analysis. Other false positive substitution types would not 
produce any mutation signature unless the false positives were a result of a context-
specific artefact. We also visually inspected the sequencing read alignments at 
predicted somatic mutation sites in the genes shown in Fig. 2/Supplementary Table 
2A and 2B, Supplementary Table S5, and significantly mutated genes to check for 
false positive substitutions that may have resulted from reads that have potentially 
been mis-mapped. 
 
Somatic Mutation Calling With MuTect 
Somatic site mutations were identified from comparison of tumour and matched 
normal BAM files using MuTect (v1.1.7) (6). Default parameters were used, except in 
the following:   
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--max_alt_allele_in_normal_fraction 0.1 
--max_alt_alleles_in_normal_count 5  
--pir_median_threshold 12  
--pir_mad_threshold 1.5  
--heavily_clipped_read_fraction 0.25 
A dbSNP file (build 141) (7) and COSMIC file (v73; common SNPs removed) (8) 
were used as input to MuTect. Further filtering of calls is described below. 
 
Somatic InDel Calling With Strelka 
Strelka (v1.0.14) (9) was used to identify somatic InDels. The configuration file 
available in the Strelka package for reads aligned with BWA was used. Default 
parameters were used, with the exception of the parameters below: 
isSkipDepthFilters = 1 
indelMaxRefRepeat = 100 
indelMaxIntHpolLength = 50 
sindelNoise = 0.0000005 
minTier1Mapq = 15 
sindelQuality_LowerBound = 25 
isWriteRealignedBam = 1 
Additional arguments were provided: 
‘-min-candidate-indel-reads 4 -min-small-candidate-indel-read-frac 0.05 -min-
candidate-indel-read-frac 0.05’ 
Further filtering of calls is described below. 
 
Filtering SNVs and InDels 
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SNVs and InDels falling within the bait regions defined by the Agilent SureSelectXT 
Human All Exome v5 bait regions plus 100bp flank were included in analyses. 
Variants were compared to those found in the ExAc database (10) and removed if 
present with a population allele frequency >=1%.  Variants determined to be false 
positives from Sequenom MassARRAY iPLEX genotyping were removed. Read 
alignments for genes of interest (Fig. 2 in the main text) were inspected using the 
Integrative Genomics Viewer (IGV) (11) to verify the presence of somatic mutations, 
and to compare 15G1 and 15G2 for calls that may have been missed. 
In counting and analysis of mutations in the exomes, all mutations falling within 
exons and affecting splice acceptor and splice donor sites were (12)included. 
 
Predicting Variant Consequences With Variant Effect Predictor (VEP) 
The Ensembl Variant Effect Predictor (VEP) (12) software was used to predict the 
effect of somatic and germline variants on protein sequences. Gene models from 
Ensembl (13) release 81 which is based on the reference genome version GRCh37 
(14) were used. Variants in genes with the Ensembl biotype designation ‘protein 
coding’ and those affecting protein coding regions or essential splice sites in targeted 
exome regions were retained for downstream analyses, and only the effects on 
canonical transcripts were considered. For genes shown in Fig. 2, if multiple 
mutations were observed in the same gene, and the predicted effects of the 
mutations on the protein sequence were different, then only the highest priorty effect 
was shown in Fig. 2. The priority, from highest to lowest, was “splice acceptor 
variant”, “stop gained”, “framehshift variant”, “inframe insertion”, “inframe deletion”, 
and “missense variant”. This order of priority is based on the estimated severity of the 
effects as determined by Ensembl 
(http://www.ensembl.org/info/genome/variation/predicted_data.html). The full list of 
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mutations and consequences for genes in Fig. 2 is in Supplementary Tables S2A - 
S2B. 
Validation of Somatic Variants 
A random selection of 529 somatic variant sites (379 SNVs, 110 small deletions and 
40 small insertions) affecting coding regions or essential splice sites, plus 50 non-
silent mutations in the genes APC, KRAS, MLH1, MSH2, MSH3, MSH6, POLE, 
POLD1, TP53, MUTYH, APOBEC3A and APOBEC3B (41 SNVs, 8 small deletions, 1 
small insertion) were subjected to validation using the Sequenom MassARRAY 
iPLEX genotyping platform 15. Eight of the 579 variant sites selected were also 
called in at least one other tumour sample; including these recurrent variants, a total 
of 595 variant sites were available to estimate the false positive rates. Genotyping 
assays were performed across all tumours and matched normal samples. Fourty-nine 
validation sites either failed the Sequenom assay or had an ‘N’ base call in the 
sample with the predicted variant base (or its matched normal), leaving 546 assays 
to estimate the false positive rates which were 15% (59/402) for SNVs, 11% (12/109) 
for small deletions, and 23% (8/35) for small insertions. Of the mutations in the genes 
of interest in Fig. 2, for 41% we were unable to perform validation, primarily due to 
lack of DNA. The remainder of the mutations in Fig. 2 have been verified as somatic 
mutations. Eight mutations in these genes were false positives and not included in 
Fig. 2. We used PCR amplification and Sanger sequencing to confirm the presence 
or absence of each hotspot InDel in ACVR2A, RPL22, and RNF43 (Fig. 4A) in 8 
hypermutator tumour samples and their matched normal samples to confirm the 
somatic status of the InDels. We did not have sufficient DNA for 2 hypermutator 
samples, 20Y and 15G2, and thus these samples were excluded. In the remaining 
samples, the somatic hotspot InDels in these 3 genes were confirmed, with the 
exception of the RPL22 p.K15fs mutation which we could not confirm due to low 
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quality sequencing results. Examples of chromatograms generated from Sanger 
sequencing validation are shown in Supplementary Fig. S7.  All chromatograms were 
visually inspected for the presence or absence of the expected InDel, and confirmed 
using the web application Indigo (https://gear.embl.de/indigo). We also confirmed the 
presence or absence of the DOCK3 p.T1850fs mutation in the hypermutator cases 
(Supplementary Table S7), which was identified as a driver event in a much larger 
cohort of sporadic CRC (15) but failed to reach significance in our analysis. All read 
alignments for mutations in Fig. 2 and Fig. 4A were also visually inspected using the 
Integrated Genomics Viewer (11). A complete list of somatic mutations is available in 
Supplementary Table S7 - S8, and those that have been validated using the 
Sequenom MassARRAY platform and Sanger sequencing are indicated. 
The region of interest in the RPL22, RNF43, ACVR2A, and DOCK3 genes was 
amplified from genomic DNA using Thermo Scientific Thermo-Start Taq DNA 
Polymerase (following manufacturer’s instructions) and the oligo pairs below. The 
expected product sizes were 301, 282, 284, and 276bp, respectively. The resulting 
amplified products were sequenced by Sanger sequencing (Eurofins) using the same 
oligos. 
 
RPL22 Forward                 5' CCCCAGTAGGTTTTCTCAACA 3' 
RPL22 Reverse                   5' AGCACACTTCCGTTAGTTTTG 3' 
RNF43 Forward                 5' GTCCACAGATCAAGGGGTGT 3' 
RNF43 Reverse                  5' GGCTCTCTAACCCACAGTGC 3' 
ACVR2A Forward             5' CCAGTTTGAAAGTCAGGAGGA 3' 
ACVR2A Reverse               5' TGCAGAAGAAAGAGAAATGTGC 3' 
DOCK3 Forward                 5' CCCAGGGGACTCTTCTCAT 3' 
DOCK3 Reverse                 5' TTCCTCCTGTAGACCCCAAG 3' 
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Annotation of Variants With ClinVar Clinical Significance 
A ClinVar database (16) VCF file (release date 2016-05-31) was downloaded from 
the ClinVar FTP site (17). All somatic mutations were annotated with ClinVar clinical 
significance. To identify potentially clinically relevant variants in the germline exomes, 
variants identified in the normal lymph node samples were also compared to variants 
in the files ‘common_and_clinical.vcf.gz’ and 
‘common_no_known_medical_impact.vcf.gz’ (release date 2016-05-31), also 
downloaded from the ClinVar FTP site. These represent variants that are common in 
the general population but are clinically relevant, and common variants that are not 
known to have medical impact, respectively. Filtering of germline variants using this 
information is described below. 
 
Variant Calling in Germline Exomes 
For each of the normal lymph node samples, SAMtools (v1.3) (18) and bcftools (v1.3) 
(19) were used to identify variants relative to the human reference genome GRCh37, 
and bcftools ‘norm’ was used to left-align all InDel calls and split mutliallelic sites into 
multiple rows. Soft-filtering of variant calls was performed using bcftools ‘filter’ and 
only calls annotated as ‘PASS’ were considered for downstream analyses. The 
following parameters were used: 
SAMtools mpileup -C50 -pm4 -F0.2 -d1000 -ug -t DP,DPR,DV,DP4,INFO/DPR,SP  
bcftools call -vm 
bcftools norm -m -  –D –T baits_w100.bed 
bcftools filter -m+ -sLowQual -e\"%QUAL<=10\" -g3 -G5 -Ov –T baits_w100.bed 
where the file baits_w100.bed is a BED file containing genomic regions defined by 
the Agilent SureSelectXT Human All Exome v5 baits with 100bp flank on each side.  
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Variant consequences were predicted using the Variant Effect Predictor as described 
above.  We identified germline variants in genes implicated in familial CRC 
(Supplementary Table S4) (20) and searched for these variants in the ClinVar 
database (release 2016-05-31) (16) to determine their clinical significance.  We 
removed variants that are found in dbSNP build 147 (21) which were common SNPs 
with no known medical impact (see above) and variants found in the ClinVar 
database and classified with a clinical significance of ‘benign’ or ‘likely benign’. 
Variants found in the ClinVar database classified as ‘pathogenic’, ‘unknown’ or 
‘untested’, common SNPs with known medical impact (see above), or not found in 
the ClinVar or dbSNP databases were considered variants of interest for 
Supplementary Table S5 if the variant was absent from the ExAc database (10) or 
present with an allele frequency less than 0.01. 
 
Identification of Somatic Copy Number Alterations (SCNA) with Sequenza 
The Sequenza software package (version 2.1.2) (22) was used to estimate tumour 
cellularity and ploidy, and to obtain allele-specific copy number profiles 
(Supplementary Table S6). For data preprocessing, SAMtools (v1.3) (18) was used 
to generate ‘pileup’ files for each tumour an normal sample BAM file, with ‘-Q 20’ to 
skip bases with a quality score less than 20. The ‘pileup2seqz’ function in the 
sequenza-utils.py script was used to generate input files for Sequenza (v2.1.2) (22). 
All best-fit and alternative solutions for estimates of cellularity and ploidy were 
inspected manually using the contour plots, model fit and alternative fit plots, and 
chromosome copy number plots that are output by Sequenza. Samples with 
potentially noisy data were identified as those with a high estimated ploidy. Those 
with a weaving pattern of alternating copy number gain and loss as visualized in a 
genome-wide copy number plot can potentially be due to noise, or cases with a high 
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number of true SCNAs.  In cases with ploidy greater than three, an alternative 
solution with ploidy closest to 2 was chosen. However, in these cases, some of the 
copy number alteration predictions may be inaccurate. 
For each IBD-CRC sample, SCNAs were compared to recurrent SCNAs in sporadic 
CRC identified in Sheffer et al. (23) and SCNAs found in the TCGA cohort (24). We 
defined chromosome arm-level SCNAs as those with at least 90% of the 
chromosome arm deleted or amplified. All 18 broad SCNAs from Sheffer et al. (23) 
were observed in at least 1 IBD-CRC case, and many IBD-CRC cases have more 
than one recurrent Sheffer SCNA. Additionally, many of the chromosome arm-level 
SCNAs were observed at similar frequencies in IBD-CRC and both sporadic CRC 
data sets, providing confidence that the patterns of gains and losses observed in the 
genome-wide copy number plots reflect true changes rather than noise (See also 
Supplementary Table S6). 
 
Identification of Driver Genes 
For somatic mutations in the non-hypermutator cohort, we applied the software 
MutSigCV (version 1.4) (25) to find genes mutated more often than expected among 
the IBD-CRC tumour samples. Both somatic point mutations and InDels were used 
for this analysis. The required coverage file and covariates file were downloaded 
from the MutSigCV website (26) and the workflow described on the website was 
applied. Mutation Annotation Format (MAF) files where generated from the Variant 
Call Format (VCF) files produced by MuTect, and annotated by VEP (see above), 
using in-house Perl scripts. A FDR-adjusted P-value (q-value) cutoff of .1 was applied 
to select significant genes. All sequencing read alignments from SNV and InDel 
mutations in driver genes were visually inspected in the cancer and matched normal 
lymph node using the Integrated Genomics Viewer (11). For the non-hypermutators, 
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mutations occurring in exons and 50 bp surrounding exons were included to increase 
the number of mutations available for MutSigCV. We also used the dNdScv algorithm 
(27), which looks for positive selection in cancer using both SNVs and InDels in 
protein coding and splice site regions. After running dNdScv with default settings, we 
performed restricted hypothesis testing using a set of known cancer genes from the 
Cancer Gene Census (CGC) (version 81) (28). Both MutSigCV and dNdScv identified 
TP53, PIK3CA, APC, and KRAS as driver genes (q<.1) in the non-hypermutator 
cohort.  
For the hypermutator cohort, MutSigCV was run as described above, except InDels 
falling inside of microsatellites (see below) were removed prior to running MutSigCV. 
In addition, because cases 15G1 and 15G2 appear to have originated from a 
common precursor clone, the union of the mutation catalogs for these samples was 
used to avoid counting shared mutations twice. No significant genes were identified, 
likely due to lack of power (n=9). We then obtained custom scripts, required input 
files, and a modified version of MSMutSig from the author (15), which enabled us to 
run MSMutSig to identify significantly mutated genes using microsatellite InDels from 
our 7 MSI samples. MSMutSig was run with default settings, and with the assumption 
that all loci were covered in all samples. Again, no significant results were obtained, 
due to lack of power. We then applied dNdScv, which is able to analyze both the 
SNV and InDel mutations together in the hypermutator cohort (27). By default, 
dNdScv limits the number of mutations per gene per sample to 3, and the maximum 
coding mutations per sample to 3000. This excluded 15G1/2 and 4D from the 
analysis. Two InDel models are available in dNdScv; one model considers the total 
number of InDel mutations per gene, and the other model considers unique InDel 
sites per gene (the “unique-sites model”). The unique-sites model was shown to work 
well to identify true drivers in MSI tumours, while using the total number of InDels 
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finds recurrent InDel sites which may or may not be true driver mutations (27). When 
dNdSV was applied to our IBD-CRC hypermutator cases using the “unique-sites” 
model, and restricted hypothesis testing was performed as described above, only 
KRAS was identified as a driver gene (q=.08). We then used the second model for 
InDels, which allows dNdScv to consider the total number of InDels, and performed 
restricted hypothesis testing as described above. Four genes, ACVR2A (q=.03), 
KRAS (q=.03), RNF43 (q=.1), and RPL22 (q=.00006) were identified. By allowing a 
maximum FDR of 0.1, we expect < 1 false positive in this gene list. The hotspot 
InDels in ACVR2A, RNF43 and RPL22 (Fig. 4A) were validated using PCR 
amplification and Sanger sequencing in all hypermutator samples except 15G2 and 
20Y which were depleted of DNA. See “Validation of Somatic Variants” above. 
Microsatellite repeats, defined as repeats 1-6bp in size with a minimum of 5 repeat 
units, were identified in the reference genome using Phobos (29) the parameters 
used are listed below: 
-U 6  
--minPerfection 85  
–minScore 4  
–preferShorterRepeats  
–dontRemoveMostlyOverlapping  
Repeats with 5 or more repeat units were extracted from the output and somatic 
InDels falling inside any of these regions were removed from the HM MSI samples 





Mutational Spectra and Extraction of Mutational Signatures Using 
SomaticSignatures 
Mutation signatures of somatic point mutations were identified with the Bioconductor 
package SomaticSignatures (version 2.6.0) (30) using the non-negative matrix 
factorization (NMF) algorithm. Similarity between inferred signatures and the 30 
previously identified signatures from Alexandrov et al. (31-33) was measured using 
cosine similarity.  
MAF files were generated from all somatic mutations (excluding InDels) in coding 
regions and splice acceptor and donor sites for input to SomaticSignatures (v2.6.0) 
(30). Using SomaticSignatures, the frequencies of motifs were normalized to the 
frequency of 3-mers across the human genome. The non-negative matrix 
factorization (NMF) algorithm was used for decomposition, using 2-8 signatures and 
20 replicates for each round. By visual inspection of plots of residual sum of squares 
(RSS) and explained variance vs the number of signatures, and similarity to the 
Alexandrov signatures, the optimal number of signatures was deemed to be six. For 
each signature, the cosine similarity to each for the 30 Alexandrov signatures (31, 
32) was calculated, and the Alexandrov signature with the highest similarity was 
determined to be the best match (Supplementary Table S3). Signature C had highest 
cosine similarity to Alexandrov signatures 13 (.84) and 2 (.80) and is seen 
predominantly in case 21M. It is likely that both signatures are present in this sample, 
as they have previously been found together in other tumour types. 
For comparison to sporadic CRC, somatic mutation calls from a total of 386 WES of 
colon adenocarcinomas (COAD) and rectum adenocarcinomas (READ) were 
downloaded from TCGA Data Portal (6 January 2017) (34). Four samples with less 
than 10 mutations were removed, leaving 382 samples. Protein coding and splice 
site mutations from the 382 samples, identified using the Variant Effect Predictor 
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software (12) as described above, were used to generate the CRC (TCGA) mutation 
spectrum in Fig. 3A. The Giannakis et al. (35) cohort included 619 samples from the 
Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). A 
complete list of somatic mutations from this cohort was downloaded and the protein 
coding and splice site mutations were used to generate the CRC (NHS/HPFS) 
mutation spectrum in Fig. 3A Similarity of the IBD-CRC mutation spectrum to the 
spectra derived from the Giannakis et al. (35) and TCGA cohorts were measured 
using cosine similarity. 
 
Assessment of HPV Genome DNA in Case 21M 
To search for HPV DNA, all sequencing reads from case 21M were remapped to a 
reference genome that consisted of the human reference genome GRCh37 plus 
8321 viral genomes from NCBI Viral Genomes database (release 80; 
ftp://ftp.ncbi.nlm.nih.gov/refseq/release/viral/), which includes the high-risk human 
papillomavirus 16 and 18, plus 51 other HPV genomes. There were no read 
alignments to any HPV genomes, only a low level of poor alignments to repeat 
regions in other virus genomes. However, since WES sequencing was generated for 
this study, it is unlikely any viral sequence would be captured even if present. 
 
HLA and Neo-epitope Analysis  
HLA Class I 4-digit typing was performed using the HLA genotyping algorithm 
OptiType version 1.0 with default parameters (36). OptiType aligns the HLA 
sequence of the sample in question to HLA allele reference sequences and selects 
the optimal solution applying integer linear programming. To predict the number of 
neo-epitopes from missense mutations, the corresponding proteins were mapped to 
the GRCh37.74 human reference proteome. Peptides consisting of up to 17 amino 
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acids, depending on the position of the mutation in the protein (middle or termini), 
were retrieved and the affected wild-type amino acid was replaced in silico with the 
corresponding mutant amino acid for each mutant protein. Neo-epitope predictions 
were performed using the HLA-I Consensus algorithm of the Immune Epitope 
Database and Analysis Resource with 9mer sliding windows of the mutant peptides 
(37, 38). Prediction scores of all six HLA-I alleles and all sliding windows per mutant 
were considered in the analysis, therefore multiple neo-epitopes per mutation were 
possible to count. To cover most of the potential immune responses, neo-epitopes 
with a relative percentile rank ≤ 1% for each HLA-I allele were considered binders 
(39, 40). 
In the present work the IEDB consensus tool for predicting HLA-peptide binding 
affinities was employed. The “consensus” approach involves the integration of 
several HLA-peptide binding prediction algorithm scores into a single score 
(http://tools.iedb.org/mhci/). 
Since the different algorithms have different ways of “scoring” binding affinities, one 
way of integrating the different scores is by calculating percentile ranks. 
A percentile rank represents a percentage of scores in a given distribution of scores, 
and it is calculated as follows: 
 
Where B is the number of scores below a given score, S is the number of 
occurrences of a given score, and N is the total number of scores in the distribution. 
In this specific analysis, the HLA binding prediction tool generates a percentile rank 
for each peptide-HLA binding prediction method independently, by comparing a given 
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peptide-HLA binding score (e.g. IC50 value) to a set of predictions using random 
peptides from the SWISSPROT database (http://www.uniprot.org/uniprot/). Then, the 
median of the percentile ranks from the different methods for each peptide-HLA 
binding prediction is reported as the consensus percentile rank for that peptide-HLA 
prediction (http://tools.iedb.org/mhci/help/). 
Finally, the consensus percentile rank of <1% was selected according to the IEDB 
recommended threshold for HLA-I predictions (http://help.iedb.org/hc/en-
us/articles/114094151811-Selecting-thresholds-cut-offs-for-MHC-class-I-and-II-
binding-predictions). 
Nanostring Analysis  
The NanoString nCounter Analysis System (NanoString Technologies, Seattle, WA, 
USA) was used to measure immune-related gene expression. Total RNA was diluted 
with RNase-free water to 20 ng/μl. We analyzed 100 ng (5 μl) of RNA from each 
sample using the PanCancer Immune Profiling Codeset (Nanostring Technologies). 
Each sample was analyzed in a separate multiplexed reaction. The CodeSet was 
hybridized in solution for 18 h at 65 °C according to the manufacturer’s instructions. 
Hybridized samples were loaded onto the nCounter Prep Station for purification and 
immobilization followed by quantification of target RNA using the nCounter Digital 
Analyzer. Quantified expression data was imported into NanoString’s nSolver 
Analysis Software (version 2.5) for quality checking and normalization. Raw counts 
were initially normalized using the internal positive controls permitting correction of 
potential sources of variation associated with the technical platform. Normalization for 
differences in RNA input was achieved using the 15 candidate housekeeping genes 
provided by Nanostring. Twenty-four of the cancer cases were analyzed to reflect 
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IBD-CRC heterogeneity (3Q, 4D, 5J, 6J, 7F, 8E, 9N, 10L, 12N, 14G, 15G1, 15G2, 
16M, 17Z, 18F, 20Y, 21M, 22L, 23Y, 26N, 27N, 29D, 33W, 34S). 
 
MLH1 Promoter Methylation Analysis 
MLH1 promoter methylation was analyzed in a region spanning 17 CpG sites  (41), 
from -169 to 465 of the human MLH1 gene (NG_007109.2). CpG island methylation 
of this promoter region has been shown to correlate with MLH1 protein 
expression(41) and has been analyzed for MLH1 promoter methylation assessment 
in colorectal cancer (42, 43). 76-200ng of tumour DNA was bisulfite-converted and 
purified using the EZ DNA Methylation Kit Gold (Zymo Research) according to 
manufacturer’s protocol. HCT116 DNA served as a negative control and HCT116 
DNA treated with CpG Methylase M.Sss1 (M0226S, New England Biolabs) was used 
as a positive control. Promoter methylation of the X-chromosomal FMR1 gene, which 
is non-methylated in males and hemi-methylated in females(44), was assessed as an 
internal control for each sample. 1-4µl of bisulfite-treated DNA was amplified using 
GoTaq® G2 Hot Start Polymerase (M7405, Promega) and M13-tailed primers:  
MLH1 forward  
5’ TGTAAAACGACGGCCAGTGGGAGGTTATAAGAGTAGGGTTAA ’3’  
and reverse 
5’GCAGGAAACAGCTATGACCTCTCAACTCTATAAATTACTAAATCTCTT ’3’,  
FMR1 [102] forward  
5’ TGTAAAACGACGGCCAGTTGAGTGTATTTTTGTAGAAATGGG ’3’  
and reverse 
5’ GCAGGAAACAGCTATGACCTCTCTCTTCAAATAACCTAAAAAC ’3’. Cycling 
conditions (MLH1/FMR1) were 5min at 95°C, 5 cycles of 30sec at 95°C, 120sec at 
55/60°C, 180sec at 72°, 37 cycles of 30sec at 95°, 60sec at 70/65°C, 180sec at 
72°C, 15min at 72°C. Sanger sequencing using M13 forward primer 
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(5´TGTAAAACGACGGCCAGT’3´) was carried out with an Applied Biosystems 
3130xl Genetic Analyzer (Life Technologies).  
 
SYNCHRONOUS CANCERS IN IBD PATIENTS 
Previous studies reported that synchronous colorectal cancers arise in IBD patients 
with a frequency of 11%-27% (45, 46) . Two of the patients in our series had multiple 
cancers: Patient 15G had two adjacent cancers (cases 15G1 and 15G2) and had a 
clinically significant germline variation in CHEK2 and patient 32N had 3 cancers 
separated anatomically (cases 32N1, 32N2, 32N3) with an uncharacterised germline 
variation in GALNT12 (Supplementary Table S5 and Supplementary Results).  
Patient 15G was a male patient with an undefined period of colonic Crohn’s disease 
who at the age of 65 years, developed two cancers separated by a distance of 
10mm; case 15G1 showed an adenocarcinomatous pattern and 15G2 displayed a 
squamous cell carcinomatous differentiation. The two cancers from 15G had over 
2410 common mutations suggesting that they originated from the same precursor 
clone. Both cancers have shared non-silent mutations in MLH1 (I36S), PMS2 
(D544N), POLE (P286R and F348S in the exonuclease domain), POLD1 (R81W) 
and APOBEC3B (A121T) but also private mutations in POLE, POLD1, APC, MSH6, 
PMS2 and APOBEC3B. Neither have non-silent mutations in KRAS or TP53 (Fig. 2). 
15G2 has more private mutations (5646) than 15G1 (3170), however, in total 2410 
mutations are shared between the two tumours suggesting that both evolved from 
the same precursor clone. Patient 15G also had a germline frameshift variation in 
CHEK2 (T367fs, more commonly referred to in the literature as c.1100delC), which 
confers a risk of developing of breast, colon and prostate cancer (47) 
(Supplementary Table S5).  It is unclear how chronic inflammation may modulate this 
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germline variant but as CHEK2 is involved in the DNA damage response pathways 
functional deficiency may accelerate carcinogenesis (48).   
 
Patient 32N is a female who was diagnosed with autoimmune hepatitis at a young 
age and had liver cirrhosis (proven on biopsy) the following year. She has been 
treated with continuous low dose steroid and azathioprine therapy to the present day. 
It is unclear when she developed ulcerative colitis (although she had intermittent 
diarrhoea for >15 years) and colorectal cancer was discovered at the age of 33 
years. The colectomy specimen had 3 separate cancers from 3 different locations; 
case 32N1 (ascending colon) and case 32N2 (transverse colon) were 
adenocarcinomas and case 32N3 (descending colon) was a mucinous carcinoma. 
The cancers from 32N had only 6 somatic mutations common to at least 2 of the 3 
cancers. No somatic mutations were common between all 3 cancers, demonstrating 
the inter-tumour heterogeneity and indicating that these 3 cancers have arisen 
independently and synchronously on a background of chronic inflammation (Fig. 2). 
Case 32N3 is the only cancer with a MSH2 missense variant (Fig. 2), but the 
mutation signature in this tumour does not correlate with a dMMR mutational 
signature (Fig. 2), and it is not a hypermutator (Fig. 2). Germline analysis identified 
an uncharacterised GALNT12 variation (G350R) in patient 32N. GALNT12 is located 
on chromosome 9q22-33 in close proximity to a colorectal cancer linkage peak and 
GALNT12 mutations have been described in patients that develop multiple epithelial 
cancers including mucinous colon and breast cancers (49, 50). GALNT12 catalyses 
the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue, 
one of the initial steps in O-linked oligosaccharide biosynthesis (glycosylation). 
Aberrant gylcosylation has been identified in several cancers including colorectal 







1. Auton, A., Brooks, L. D., Durbin, R. M., Garrison, E. P., Kang, H. M., Korbel, J. O., 
et al. A global reference for human genetic variation. Nature 2015, 526: 68-74. 
2. Li, H. and Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler 
transform. Bioinformatics 2009, 25: 1754-1760. 
3. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., et 
al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res 2010, 20: 1297-1303. 
4. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National 
Center for Biotechnology Information, National Library of Medicine. (dbSNP Build 
ID: 135). http://www.ncbi.nlm.nih.gov/SNP/. 
5. Tischler G, L. S. biobambam: tools for read pair collation based algorithms on BAM 
files. Source Code for Biology and Medicine. . pp. 2014;2019:2013. 
doi:2010.1186/1751-0473-2019-2013., 2014. 
6. Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., 
et al. Sensitive detection of somatic point mutations in impure and heterogeneous 
cancer samples. Nat Biotechnol 2013, 31: 213-219. 
7. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National 
Center for Biotechnology Information, National Library of Medicine. (dbSNP Build 
ID: 141). http://www.ncbi.nlm.nih.gov/SNP/. 
8. Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., et 
al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. 
Nucleic Acids Res 2015, 43: D805-811. 
9. Saunders, C. T., Wong, W. S., Swamy, S., Becq, J., Murray, L. J., and Cheetham, R. 
K. Strelka: accurate somatic small-variant calling from sequenced tumor-normal 
sample pairs. Bioinformatics 2012, 28: 1811-1817. 
10. Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., et 
al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 2016, 536: 
285-291. 
11. Robinson, J. T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, 
G., et al. Integrative genomics viewer. Nat Biotechnol 2011, 29: 24-26. 
12. McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., et al. 
The Ensembl Variant Effect Predictor. Genome Biology 2016, 17: 122. 
13. Yates, A., Akanni, W., Amode, M. R., Barrell, D., Billis, K., Carvalho-Silva, D., et al. 
Ensembl 2016. Nucleic Acids Res 2015, 44: D710-716. 
14. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., et al. 
Initial sequencing and analysis of the human genome. Nature 2001, 409: 860-921. 
15. Maruvka, Y. E., Mouw, K. W., Karlic, R., Parasuraman, P., Kamburov, A., Polak, P., 
et al. Analysis of somatic microsatellite indels identifies driver events in human 
tumors. Nature Biotechnology 2017, 35: 951. 
16. Landrum, M. J., Lee, J. M., Benson, M., Brown, G., Chao, C., Chitipiralla, S., et al. 
ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids 
Res 2016, 44: D862-868. 
17. ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/vcf_GRCh37/. 
18. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., et al. The 
Sequence Alignment/Map format and SAMtools. Bioinformatics 2009, 25: 2078-
2079. 
19. Li, H. A statistical framework for SNP calling, mutation discovery, association 
mapping and population genetical parameter estimation from sequencing data. 
Bioinformatics 2011, 27: 2987-2993. 
 56
20. OMIM Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute 
of Genetic Medicine, Johns Hopkins University (Baltimore, MD). World Wide Web 
URL: http://omim.org/. 
21. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National 
Center for Biotechnology Information, National Library of Medicine. (dbSNP Build 
ID: 147). http://www.ncbi.nlm.nih.gov/SNP/. 
22. Favero, F., Joshi, T., Marquard, A. M., Birkbak, N. J., Krzystanek, M., Li, Q., et al. 
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing 
data. Ann Oncol 2015, 26: 64-70. 
23. Sheffer, M., Bacolod, M. D., Zuk, O., Giardina, S. F., Pincas, H., Barany, F., et al. 
Association of survival and disease progression with chromosomal instability: a 
genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 2009, 106: 7131-
7136. 
24. The Cancer Genome Atlas, N. Comprehensive molecular characterization of human 
colon and rectal cancer. Nature 2012, 487: 330-337. 
25. Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, 
A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated 
genes. Nature 2013, 499: 214-218. 
26. http://www.broadinstitute.org/cancer/cga/mutsig_run. 
27. Martincorena, I. i., Raine, K. M., Gerstung, M., Dawson, K. J., Haase, K., Van Loo, 
P., et al. Universal Patterns of Selection in Cancer and Somatic Tissues. Cell 2017, 
171: 1029-1041.e1021. 
28. Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., et al. A 
census of human cancer genes. Nature Reviews Cancer 2004, 4: 177. 
29. Mayer, C. Phobos. 3.3.11, 2006-2010. 
30. Gehring, J. S., Fischer, B., Lawrence, M., and Huber, W. SomaticSignatures: inferring 
mutational signatures from single-nucleotide variants. Bioinformatics 2015, 31: 3673-
3675. 
31. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, 
A. V., et al. Signatures of mutational processes in human cancer. Nature 2013, 500: 
415-421. 
32. Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik-Zainal, 
S., et al. Clock-like mutational processes in human somatic cells. Nat Genet 2015, 47: 
1402-1407. 
33. http://cancer.sanger.ac.uk/cancergenome/assets/signatures_probabilities.txt. 
34. The Cancer Genome Atlas homepage. http://cancergenome.nih.gov. 
35. Giannakis, M., Mu, XinmengÂ J., Shukla, SachetÂ A., Qian, ZhiÂ R., Cohen, O., 
Nishihara, R., et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal 
Carcinoma. Cell Reports 2016, 15: 857-865. 
36. Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., and Kohlbacher, O. 
OptiType: precision HLA typing from next-generation sequencing data. 
Bioinformatics 2014, 30: 3310-3316. 
37. Kim, Y., Ponomarenko, J., Zhu, Z., Tamang, D., Wang, P., Greenbaum, J., et al. 
Immune epitope database analysis resource. Nucleic Acids Res 2012, 40: W525-530. 
38. Vita, R., Overton, J. A., Greenbaum, J. A., Ponomarenko, J., Clark, J. D., Cantrell, J. 
R., et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015, 43: 
D405-412. 
39. Moutaftsi, M., Peters, B., Pasquetto, V., Tscharke, D. C., Sidney, J., Bui, H. H., et al. 
A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-
cell responses to vaccinia virus. Nat Biotechnol 2006, 24: 817-819. 
 57
40. Kotturi, M. F., Peters, B., Buendia-Laysa, F., Jr., Sidney, J., Oseroff, C., Botten, J., et 
al. The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L 
antigen: uncovering new tricks for an old virus. J Virol 2007, 81: 4928-4940. 
41. Deng, G., Chen, A., Hong, J., Chae, H. S., and Kim, Y. S. Methylation of CpG in a 
small region of the hMLH1 promoter invariably correlates with the absence of gene 
expression. Cancer Res 1999, 59: 2029-2033. 
42. Gay, L. J., Arends, M. J., Mitrou, P. N., Bowman, R., Ibrahim, A. E., Happerfield, L., 
et al. MLH1 promoter methylation, diet, and lifestyle factors in mismatch repair 
deficient colorectal cancer patients from EPIC-Norfolk. Nutr Cancer 2011, 63: 1000-
1010. 
43. Newton, K., Jorgensen, N. M., Wallace, A. J., Buchanan, D. D., Lalloo, F., McMahon, 
R. F., et al. Tumour MLH1 promoter region methylation testing is an effective 
prescreen for Lynch Syndrome (HNPCC). J Med Genet 2014, 51: 789-796. 
44. Boyd, V. L., Moody, K. I., Karger, A. E., Livak, K. J., Zon, G., and Burns, J. W. 
Methylation-dependent fragment separation: direct detection of DNA methylation by 
capillary electrophoresis of PCR products from bisulfite-converted genomic DNA. 
Anal Biochem 2006, 354: 266-273. 
45. Lam, A. K., Chan, S. S., and Leung, M. Synchronous colorectal cancer: clinical, 
pathological and molecular implications. World J Gastroenterol 2014, 20: 6815-6820. 
46. Greenstein, A. J., Slater, G., Heimann, T. M., Sachar, D. B., and Aufses, A. H., Jr. A 
comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial 
polyposis coli, and de novo cancer. Ann Surg 1986, 203: 123-128. 
47. Huijts, P. E., Hollestelle, A., Balliu, B., Houwing-Duistermaat, J. J., Meijers, C. M., 
Blom, J. C., et al. CHEK2*1100delC homozygosity in the Netherlands--prevalence 
and risk of breast and lung cancer. Eur J Hum Genet 2014, 22: 46-51. 
48. Sohn, J. J., Schetter, A. J., Yfantis, H. G., Ridnour, L. A., Horikawa, I., Khan, M. A., 
et al. Macrophages, nitric oxide and microRNAs are associated with DNA damage 
response pathway and senescence in inflammatory bowel disease. PLoS One 2012, 7: 
e44156. 
49. Guda, K., Moinova, H., He, J., Jamison, O., Ravi, L., Natale, L., et al. Inactivating 
germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 
in human colon cancers. Proc Natl Acad Sci U S A 2009, 106: 12921-12925. 
50. Clarke, E., Green, R. C., Green, J. S., Mahoney, K., Parfrey, P. S., Younghusband, H. 
B., et al. Inherited deleterious variants in GALNT12 are associated with CRC 
susceptibility. Hum Mutat 2012, 33: 1056-1058. 
51. Tran, D. T. and Ten Hagen, K. G. Mucin-type O-glycosylation during development. J 






Supplementary Figure S1: Exome sequencing fold coverage of inflammatory 
bowel disease associated colorectal cancer cases and matched normal lymph 
nodes. 
Mean sequencing fold coverage (blue) of 34 Inflammatory Bowel Disease Colorectal 
Cancer (IBD-CRC) cases and matched normal lymph nodes (LN). WES yielded 
 58
between 45- and 90-fold coverage of the cancer samples and 26- to 93-fold coverage 
of the normal lymph node samples. Shown in red is the percentage of exome bases 
with less than 5-fold sequencing coverage. 
 
Supplementary Figure S2 Mismatch repair protein expression analysis. 
Cancer case 33W, a hypermutator, shows loss of expression of MLH1 (top left) and 
PMS2 (top right) and no loss of expression of MSH2 (bottom left) and MSH6 (bottom 
right) in the cancer tissue compared with the surrounding stromal tissue. 
Supplementary Figure S3: CpG island methylation of MLH1 promoter region. 
Representative chromatograms of bisulfite-sequencing analysis of the MLH1 
promoter from -169 to -465, comprising 17 CpG islands. (A) Chromatogram of a non-
methylated sample (case 16M) without any cytosines, indicating complete conversion 
of cytosine to uracil and thus no methylation. (B) Chromatogram of a methylated 
sample (case 27N) with asterisks indicating CpG islands, where cytosines either 
appear as Cs, or as C and T double peaks, indicating CpG island methylation. 
 
Supplementary Figure S4: Rainfall plot for case 21M. 
Somatic mutations are ordered along the horizontal axis according to genomic 
position. The intermutation distance is the genomic distance between a mutation and 
the previous neighbouring mutation. No clusters of mutations (as seen with kataegis) 
are evident in case 21M.  
Supplementary Figure S5: Proportion of IBC-CRC genomes with SCNAs. 
Shown are the total size of all genomic regions with predicted somatic copy number 
loss (blue), somatic copy number gain (red) in each tumour genome. Tumours are 
listed left to right in order of mutator status and decreasing mutation rate.  
Supplementary Figure S6: Nanostring nCounter® pan-cancer immune panel 
analysis. 
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Euclidian distance based unsupervised hierarchical clustering of selected IBD-CRC 
cases, based on their expression values in the cytokine gene subset of the 
Nanostring nCounter® pan-cancer immune panel. The gene expression colour scale 
range represents under-expressed transcripts in blue and over-expressed transcripts 
in red. The top panel denotes the site of tumour, and the next panel describes 
mutator phenotype; hypermutator (red) and non-hypermutator (blue). Four 
hypermutated cases (6J, 4D, 26N and 15G1) cluster strongly. 
Supplementary Figure S7: Validation of InDel mutations. 
Shown are chromatograms generated from Sanger sequencing of regions with 1bp 
deletions in (a) ACVR2A, (b) RPL22, and (c) RNF43 in tumour samples 28E, 27N 
and 33W, respectively, and their respective matched normal sample. The tumour 
samples have overlapping and shifted traces at the locations marked, which are not 
observed in the matched normal samples, indicating the presence of a somatic 1bp 
deletion in each tumour. The chromatograms have been cropped to show the 
relevant regions only. 
 
 
 
 
